Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE:002020)
China · Delayed Price · Currency is CNY 12.41
+0.11 (0.89%)
Jun 12, 2026, 3:04 PM CST
SHE:002020 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,946 | 3,980 | 4,086 | 3,920 | 3,717 | 3,401 |
Other Revenue | 89.83 | 89.83 | 72.73 | 78.89 | 62.81 | 65.06 |
| 4,036 | 4,069 | 4,159 | 3,999 | 3,780 | 3,467 | |
Revenue Growth (YoY) | -0.43% | -2.15% | 3.99% | 5.79% | 9.04% | 6.40% |
Cost of Revenue | 2,014 | 2,063 | 2,098 | 1,988 | 1,774 | 1,547 |
Gross Profit | 2,022 | 2,007 | 2,061 | 2,011 | 2,006 | 1,920 |
Selling, General & Admin | 808.23 | 822.87 | 916.32 | 994.61 | 984.94 | 970.72 |
Research & Development | 363.68 | 367.99 | 383.48 | 400.79 | 367.04 | 334.14 |
Other Operating Expenses | 59.08 | 39.78 | 33.52 | 30.09 | 36.19 | 26.57 |
Operating Expenses | 1,233 | 1,237 | 1,346 | 1,432 | 1,392 | 1,342 |
Operating Income | 789.1 | 769.85 | 714.56 | 579.08 | 613.8 | 577.8 |
Interest Expense | -3.4 | -3.96 | -7.74 | -7.31 | -6.01 | -4.97 |
Interest & Investment Income | 73.75 | 78.58 | 80.2 | 66.71 | 85.05 | 96.29 |
Currency Exchange Gain (Loss) | -10.02 | -10.02 | 2.93 | 3.43 | 14.43 | -3.84 |
Other Non Operating Income (Expenses) | -15.56 | -2.04 | -3.4 | -0.97 | -3.21 | -7.19 |
EBT Excluding Unusual Items | 833.87 | 832.42 | 786.54 | 640.94 | 704.06 | 658.09 |
Impairment of Goodwill | -12.88 | -12.88 | - | - | - | - |
Gain (Loss) on Sale of Investments | 10.34 | 9.47 | -42.37 | 24.44 | 10.15 | 7.23 |
Gain (Loss) on Sale of Assets | 2.42 | -0.57 | 2.59 | 6.86 | 0.61 | -0.48 |
Asset Writedown | -15.84 | -2.81 | -0.07 | -0.01 | -0.07 | -8.42 |
Other Unusual Items | 44.56 | 38.7 | 97.3 | 35.81 | 35.56 | 43.12 |
Pretax Income | 862.48 | 864.33 | 843.98 | 708.04 | 750.32 | 699.54 |
Income Tax Expense | 95.05 | 97.66 | 124.85 | 84.62 | 82.49 | 81.57 |
Earnings From Continuing Operations | 767.44 | 766.67 | 719.13 | 623.42 | 667.82 | 617.96 |
Minority Interest in Earnings | -7.55 | -8.69 | -7.16 | -4.52 | -5.57 | -5.42 |
Net Income | 759.89 | 757.98 | 711.96 | 618.9 | 662.25 | 612.54 |
Net Income to Common | 759.89 | 757.98 | 711.96 | 618.9 | 662.25 | 612.54 |
Net Income Growth | 7.93% | 6.46% | 15.04% | -6.55% | 8.12% | -6.21% |
Shares Outstanding (Basic) | 826 | 824 | 858 | 860 | 860 | 817 |
Shares Outstanding (Diluted) | 826 | 824 | 858 | 860 | 860 | 817 |
Shares Change (YoY) | -2.55% | -3.95% | -0.21% | -0.06% | 5.31% | 2.55% |
EPS (Basic) | 0.92 | 0.92 | 0.83 | 0.72 | 0.77 | 0.75 |
EPS (Diluted) | 0.92 | 0.92 | 0.83 | 0.72 | 0.77 | 0.75 |
EPS Growth | 10.76% | 10.84% | 15.28% | -6.49% | 2.67% | -8.54% |
Free Cash Flow | 612.37 | 578.5 | 475.52 | 273.32 | 340.2 | -33.37 |
Free Cash Flow Per Share | 0.74 | 0.70 | 0.55 | 0.32 | 0.40 | -0.04 |
Dividend Per Share | 0.350 | 0.350 | 0.350 | 0.300 | 0.300 | 0.300 |
Dividend Growth | - | - | 16.67% | - | - | 2.84% |
Gross Margin | 50.09% | 49.31% | 49.56% | 50.30% | 53.06% | 55.39% |
Operating Margin | 19.55% | 18.92% | 17.18% | 14.48% | 16.24% | 16.67% |
Profit Margin | 18.83% | 18.63% | 17.12% | 15.48% | 17.52% | 17.67% |
Free Cash Flow Margin | 15.17% | 14.22% | 11.43% | 6.83% | 9.00% | -0.96% |
EBITDA | 1,053 | 1,037 | 996.1 | 784.87 | 766.56 | 713.89 |
EBITDA Margin | 26.08% | 25.48% | 23.95% | 19.63% | 20.28% | 20.59% |
D&A For EBITDA | 263.53 | 267.13 | 281.55 | 205.79 | 152.76 | 136.09 |
EBIT | 789.1 | 769.85 | 714.56 | 579.08 | 613.8 | 577.8 |
EBIT Margin | 19.55% | 18.92% | 17.18% | 14.48% | 16.24% | 16.67% |
Effective Tax Rate | 11.02% | 11.30% | 14.79% | 11.95% | 10.99% | 11.66% |
Revenue as Reported | 4,036 | 4,069 | 4,159 | 3,999 | 3,780 | 3,467 |
Advertising Expenses | - | - | - | - | - | 5.13 |